Formulation & Evaluation of Fast Dissolving Tablets to treat migraine | A potent anti migraine drug

Piyush Agarwal (u. a.)

ISBN 10: 3659695483 / ISBN 13: 9783659695483

Published by LAP LAMBERT Academic Publishing, 2015

About this Item

Formulation & Evaluation of Fast Dissolving Tablets to treat migraine | A potent anti migraine drug | Piyush Agarwal (u. a.) | Taschenbuch | 92 S. | Englisch | 2015 | LAP LAMBERT Academic Publishing | EAN 9783659695483 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.

Seller Inventory # 104697287

Bibliographic Details

• Title: Formulation & Evaluation of Fast Dissolving Tablets to treat migraine | A potent anti migraine drug
• Publisher: LAP LAMBERT Academic Publishing
• Publication Date: 2015
• Language: English
• ISBN 10: 3659695483
• ISBN 13: 9783659695483
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 6D millimeters 220 millimeters width by 150 millimeters height by 6 millimeters depth
• Weight: 155 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

Fast dissolving tablet (FDT) technology is one of the recent innovative technologies in pharmaceutical formulations, and the FDTs formulation has become a fast-growing in oral drug delivery system. FDTs can be administered easily without water , although talking water makes oral administration even easier. They are suitable for children, the elderly and anyone who has a difficulty in swallowing conventional solid dosage forms. The FDT formulation combines advantages of both solid and liquid dosage forms and the easy administration and no risk of suffocation of liquid formulations. Application of FDT technology can be extended to patients requiring daily medication. Moreover, the technology can give a new dosage from strategy as a life-cycle management tool for drugs near the end of their patent life. In this work fast dissolving tablets of Rizatriptan benzoate were prepared to provide rapid dissolution of drug and absorption to produce rapid on-set of action in the treatment of moderate – to – severe migraine attacks in patients.